DBV Technologies S.A. (DBVT) AI Stock Analysis

DBV Technologies S.A. is a clinical-stage biopharmaceutical company headquartered in Montrouge, France, focused on developing epicutaneous immunotherapy products for food allergies and immune-related conditions. Its lead product candidate, Viaskin Peanut, completed Phase III clinical trials for peanut allergies across children, adolescents, and adults. The company is also evaluating Viaskin Milk in Phase I/II trials for cow's milk protein allergy and developing pre-clinical candidate Viaskin Egg. Additional early research targets whooping cough, respiratory syncytial virus, Crohn's disease, celiac disease, and type I diabetes. DBV Technologies partners with Nestle Health Science on MAG1C, an atopy patch test diagnosing cow's milk protein allergy in infants and toddlers.

Revenue has exhibited high volatility, dropping from $11.3M in FY2020 to $5.7M in FY2021 and $4.8M in FY2022 before jumping to $15.7M in FY2023. In FY2024, revenue fell 83.7% to $2.6M, resulting in a 5-year revenue CAGR of -29.5% from FY2019 to FY2024. Gross margin stood at -265.3% in FY2024, alongside an operating margin of -4693.4% and R&D expense of $89.9M. FY2024 net income was -$113.7M, or -$8.47 per share. Trailing twelve-month revenue as of June 30, 2026, totaled $5.0M, with quarterly revenue falling 53.3% year-over-year. Operating margin TTM was -7228.6%, and EPS TTM stood at -$3.50.

As of June 30, 2026, DBV Technologies held $174.9M in cash and short-term investments against $21.0M in total debt, yielding net cash of $153.9M. Total assets stood at $223.2M and shareholders' equity was $160.4M. Its liquidity profile includes a current ratio of 3.72 and a debt-to-equity ratio of 0.13. Cash flow remains negative, as FY2024 operating cash flow was -$104.5M and free cash flow was -$106.8M. Capital expenditures were $533,642 in FY2025, while the share count rose 55.9% over five years.

At $9.05 per share, DBV Technologies carries a market cap of $568.8M and an enterprise value of $603.7M. The stock trades at a price-to-sales multiple of 112.9x, substantially higher than the 4.1x median for its US-listed Healthcare peers. Its price-to-book ratio is 5.0x, and EV-to-revenue is 24.3x. Over the past year, the stock fell 46.8%, underperforming the S&P 500 (SPY) return of 16.8%. Over five years, DBVT is down 82.9% compared to an 83.0% gain for the benchmark index.

Wall Street coverage consists of 5 Strong Buy, 1 Buy, 0 Hold, 0 Sell, and 1 Strong Sell ratings. The mean price target is $38.74, implying 328.1% upside from the last close of $9.05. For the fiscal year ending December 31, 2026, analysts expect revenue of $3.6M and EPS of -$0.46. For the next fiscal year, 4 analysts model revenue of $62.3M, representing 1630.2% growth, alongside an EPS estimate of -$0.43. The company beat EPS estimates in 2 of the last 4 quarters, with its next earnings date scheduled for October 27, 2026.

This page is an AI-written research summary of DBV Technologies S.A. (DBVT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: DBVT income statement, DBVT balance sheet, DBVT key metrics, DBVT analyst forecast, DBVT chart. See the DBVT stock overview for the latest quote and news.